LivaNova PLC (NASDAQ:LIVN) shares climbed nearly 2% in premarket trading Wednesday after the medical technology firm delivered third-quarter earnings and revenue that beat Wall Street expectations and raised its full-year guidance.
The cardiac and neurological device maker reported adjusted earnings of $1.11 per share, topping analyst estimates of $0.92, while revenue came in at $357.8 million, above the expected $342.7 million and up 12.5% year over year on a reported basis.
Growth was led by the Cardiopulmonary segment, where revenue surged 18% to $203.2 million, fueled by strong demand for the Essenz Perfusion System and robust consumables sales across global markets. The Neuromodulation division also contributed positively, with revenue up 6.9% to $149.5 million.
“LivaNova delivered another quarter of double-digit revenue growth, underscoring the durability of our Cardiopulmonary and Epilepsy businesses as a strong foundation for the Company,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova.
Building on the strong quarter, LivaNova raised its full-year 2025 outlook. The company now expects adjusted earnings per share between $3.80 and $3.90, compared to its previous forecast of $3.70 to $3.80, and above the consensus estimate of $3.76. Revenue growth guidance was also increased to 8.5%–9.5% on a constant-currency basis, up from 8%–9%.
Additionally, LivaNova lifted its adjusted free cash flow forecast to a range of $160 million–$180 million, representing a $20 million increase at the midpoint from prior expectations.
The company also announced the commercial launch of its Essenz Perfusion System in China, which it described as the second-largest market for heart-lung machines after the United States, further expanding its global footprint in life-support technology.